Knowledge on the effects of gabapentin (GBP) in learning disabled patients is limited. The objective of this study was to assess antiepileptic efficacy and tolerability of GBP in routine therapy. A retrospective open observational study design was applied. Twenty-nine consecutive residential patients with simple and/or complex partial seizures with or without secondary generalization and with different degrees of learning disability were included. All patients had severe therapy-resistant epilepsy. GBP was administered as add-on therapy. Dosages were progressively increased up to 1600-2400 mg/day (in a number of cases up to 4800 mg/day), in accordance with clinical requirements. The seizure frequency was recorded and compared between a baseline and a treatment period (after 3 months of titration) of 3 months duration each.
Dear Sir, The few reports on the use of gabapentin (GBP) in the antiepileptic treatment of learning-disabled patients are very positive, indicating responder rates from 34 to 56% [1] [2] [3] . We do not want to miss to communicate that our own experience of a large institution specializing in long-term treatment of chronic epilepsy in the learning disabled is much more disappointing.
As any new antiepileptic drug is hopeful for therapy-resistant patients, GBP started to be used in Bethel after its introduction to the market.
The objective of this study was to assess efficacy and tolerability of the new drug in routine therapy. To avoid the ethical and legal difficulties of controlled studies conducted in handicapped patients, the method of an open observational study in accordance with the guidelines published by Linden 4 was chosen. Twenty-nine consecutive adult patients with simple and/or complex partial seizures with or without secondary generalization who were treated with GBP between 1996 and 1998 were included. All patients were in long-term residential care in the Bethel Epilepsy Centre (mean duration of residential care: 18.8 years) because of their severe epilepsy (mean duration of epilepsy: 32.4 years) and additional impairments.
The physicians of the Bethel medical service (mostly neurologists, one pediatrician, all with special experience in the diagnosis and treatment of epilepsy) selected the patients on clinical grounds, preferably patients with frequent and/or disabling seizures. Resistance against at least one traditional AED was precondition, but in fact nearly all study participants were resistant against several traditional AEDs up to maximum tolerable dosages and in several cases against one or two new AED (mostly LTG).
Diagnoses of epilepsy and seizure types were based on the seizure descriptions and EEG findings found in the patients' case histories.
All patients or their legal representatives had given consent in GBP treatment. In a number of patients more than one side effect occurred.
According to the character of the study, there was no fixed titration scheme. Usually, GBP treatment was started on low dosages (e.g. 300-400 mg/day), followed by progressive dosage increases up to 1600-2400 mg/day, in accordance with clinical requirements. In a number of cases, the GBP dosage was further increased up to a maximum daily dose of 4800 mg. The aim was to obtain the best possible antiepileptic effects. Concomitant medication could be adjusted, when clinically appropriate.
Data with respect to seizure frequency and treatment details were retrospectively extracted from the continual records of seizures kept on all resident patients. Most of the seizure documentation and classification was done by trained and experienced staff. This ensured that the documentation was as complete as possible.
The seizure frequency was compared between a baseline and a treatment period (after 3 months of titration) of 3 months duration each.
RESULTS
Eleven patients had mild, 9 had moderate, 2 had severe (1: undetermined) learning disability. Six patients had borderline intelligence or only neuropsychological deficits like psychomotor slowing or memory disturbance.
The comedication, most frequently carbamazepine or valproate, remained widely stable throughout the trial.
Only three patients (10.3%) had a reduction of their seizure frequency by 50% or more (responders). No patient became completely seizure-free. The three responders had a wide variety of GBP daily doses (900-3200 mg/day) and serum concentrations (0.38-4.32 µg/ml).
Eleven patients (37.9%) experienced unwanted side effects ( Table 1 ). The spectrum of side effects corresponded well to the literature, somnolence and ataxia being the most frequently observed unwanted effects. They were dose-dependent, mostly mild, and disappeared after dose reduction. In two cases, we saw hyperphagia with weight increase, and in two other cases edema. (In one additional case which was not included in the study because she had generalised seizures, a dose as low as 400 mg/day caused severe somnolence. Intolerance against small doses of AED is a phenomenon not so unusual in the treatment of severely handicapped patients.)
The responder rate of only 10.3% found in our study is much lower than reported in the literature. This discrepancy is most probably due to differences in patient selection, the Bethel residential patients probably being one of the most highly therapy-resistant patient groups.
We have earlier reported on similar studies with lamotrigine (LTG) and topiramate (TPM) in the same population (although not necessarily in the same patients) with considerably higher responder rates of 28.8% 5 (LTG), respectively, 37.5% 6 (TPM). In a further study with levetiracetam, the responder rate was 41.3% (unpublished data). Marson 7 , in an attempt to compare six new AED, calculated the odds ratios as a measure of efficacy. Although all confidence intervals were overlapping, it was interesting to note the GBP odds ratio was lower than those of LTG, tiagabine, TPM, vigabatrin, and zonisamide.
We conclude GBP, although well tolerated in most cases, is not the treatment of choice in learningdisabled patients with highly therapy-resistant partial seizures because its efficacy in this difficult-to-manage patient group is limited.
